Key result
In elderly patients with known CHF, exposure to indomethacin (OR 2.04; 95% CI 1.16-3.58) or rofecoxib (OR 1.58; 95% CI 1.19-2.11) was associated with a higher risk of CHF readmission than celecoxib.
Why the study?
Does the use of individual NSAIDs or rofecoxib increase the risk of readmission for CHF compared with celecoxib in elderly patients with known CHF?
Population
42,560 elderly patients with known congestive heart failure, comprising 8,512 cases and 34,048 matched…
Comparison
Current use of naproxen, diclofenac, ibuprofen… vs Current use of celecoxib in the 7 days prior to…
Design
Case-control
Authors
Loading...
May support preferring celecoxib over indomethacin or rofecoxib in elderly CHF; observational data leave open causality and practice change.
Case-Control (n=42,560)
Does the use of individual NSAIDs or rofecoxib increase the risk of readmission for CHF compared with celecoxib in elderly patients with known CHF?
Odds Ratio: 2.04 (95% CI 1.16–3.58)
In elderly patients with known CHF, the use of indomethacin and rofecoxib is associated with a significantly higher risk of recurrent CHF compared with celecoxib.
Hudson et al. (2007) conducted a case-control in Congestive heart failure (n=42,560). Indomethacin vs. Celecoxib was evaluated on Readmission for CHF (OR 2.04, 95% CI 1.16-3.58). In elderly patients with known CHF, exposure to indomethacin (OR 2.04; 95% CI 1.16-3.58) or rofecoxib (OR 1.58; 95% CI 1.19-2.11) was associated with a higher risk of CHF readmission than celecoxib.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: